Authors: Patnaik, A Rowinsky, EK Tammara, BK Hidalgo, M Drengler, RL Garner, AM Siu, LL Hammond, LA Felton, SA Mallikaarjun, S Von Hoff, DD Eckhardt, SG

Citation: A. Patnaik et al., Phase I and pharmacokinetic study of the differentiating agent vesnarinonein combination with gemcitabine in patients with advanced cancer, J CL ONCOL, 18(23), 2000, pp. 3974-3985

Authors: Hidalgo, M Villalona-Calero, MA Eckhardt, SG Drengler, RL Rodriguez, G Hammond, LA Diab, SG Weiss, G Garner, AM Campbell, E Davidson, K Louie, A O'Neil, JD von Borstel, R Von Hoff, DD Rowinsky, EK

Citation: M. Hidalgo et al., Phase I and pharmacologic study of PN401 and fluorouracil in patients withadvanced solid malignancies, J CL ONCOL, 18(1), 2000, pp. 167-177

Authors: Villalona-Calero, MA Weiss, GR Burris, HA Kraynak, M Rodrigues, G Drengler, RL Eckhardt, SG Reigner, B Moczygemba, J Burger, HU Griffin, T Von Hoff, DD Rowinsky, EK

Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925

Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML

Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696